Health&Beauty- Page 23

PFIZER REPORTS POSITIVE CLINICAL DATA FOR BCMA-CD3 BISPECIFIC ANTIBODY (PF-06863135) IN MULTIPLE MYELOMA

The FINANCIAL -- Pfizer Inc. (NYSE:PFE) announced safety and clinical response results from the ongoing Phase 1 study (NCT03269136) for PF-06863135, an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody. Data from 30 patients with relapsed or refractory multiple myeloma showed manageable safety
December 8, 2020
3 mins read
1 … 21 22 23 24 25 … 121

Get updates

Join

We hate spams like you do

Latest comments

Go toTop